Overzicht lopende oncologische studies​


A Phase 1b Study of Talimogene Laherparepvec in Combination With Atezolizumab in Subjects With Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases.

  • Atezolizumab (anti-PD-L1) IV in combinatie met TVEC injecties in levermetastasen


A Phase 1b/2, Multicenter, Open-label, Basket Trial to Evaluate the Safety of Talimogene Laherparepvec Injected into Liver Tumors Alone and in Combination With Systemic Pembrolizumab in Phase 1b and to Evaluate the Efficacy and Safety of Intratumoral Talimogene Laherparepvec in Combination With Systemic Pembrolizumab to Treat Subjects with Advanced Solid Tumors in Phase 2.

  • Intratumorale injecties met T-Vec al dan niet in combinatie met Pembrolizumab IV


A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-181, as Monotherapy and in Combination with Another Anti-Cancer Therapy in Subjects with Advanced Solid Tumors. (M15-891).

  • ABBV-181 (nieuw anti-PD1 antilichaam) in monotherapie of in combinatie met ofwel Rova-T ofwel Venetoclax


An open-label, multicenter, phase II study to evaluate the therapeutic activity of RO6874281, an immunocytokine, consisting of interleukin-2 variant (IL-2v) targeting fibroblast activation protein-A (FAP), in combination with atezolizumab (anti-PD-L1), administered intravenously, in participants with advanced and/or metastatic solid tumors.

  • Atezolizumab (anti-PD-L1) in combinatie met RO6874281 (FAP-targeted IL-2v)


Phase I/Ib First-in-Human study of EOS100850 in patients with advanced solid tumors.

  • Behandeling met EOS100850, een orale adenosine A2a receptor antagonist, hetzij in monotherapie, hetzij in combinatie met pembrolizumab of standard-of-care chemotherapie


A Phase 1 first- in-human dose escalation and expansion study for the evaluation of safety,pharmacokinetics, pharmacodynamics and anti-tumor activity of SAR441000 administered intratumorally as monotherapy and in combination with cemiplimab in patients with advanced solid tumors

  • Intra-tumorale toediening van SAR441000, een mengsel van m-RNA’s die coderen voor cytokines, al dan niet in combinatie met cemiplimab (anti-PD1)


An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies with repeated administration in patients with clinical benefit. 

  • Monotherapie met BI 894999, een orale BET-inhibitor


A Phase 1B/2 study to evaluate safety and clinical activity of avelumab in combination with binimetinib with or without talazoparib in patients with locally advanced or metastatic RAS-mutant solid tumors.

  • Binimetinib (MEK 1/2 inhibitor) in combinatie met talazoparib (PARP inhibitor), al dan niet in combinatie met avelumab (anti-PD-L1) 


A Phase 1b Dose-Escalation Study of Cabozantinib Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors.

  • Atezolizumab (anti-PD-L1) in combinatie met Cabozantinib (tyrosine kinase inhibitor) of - in bepaalde cohorten - Cabozantinib monotherapie


A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and efficacy of prostate specific membrane antigen half-life extended bispecific T-cell engager AMG 160 in subjects with metastatic castration-resistant prostate cancer.

  • AMG160 (PSMA-targeted BiTE) in monotherapie, of in combinatie met pembrolizumab (anti-PD-1)


A phase 2 study of erdafitinib in subjects with advanced solid tumors and FGFR gene alterations.

  • Erdafitinib (FGFR inhibitor) in monotherapie


A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors.

  • INCB086550, een small-molecule PD-L1 inhibitor


A Phase I/IIa First-In-Human Study of EOS884448 in Participants with Advanced Cancers.

  • EOS884448, een anti-TIGIT monoclonaal antilichaam


A Phase 1, Open-Label, Dose-Escalation, Safety, Tolerability, and Preliminary Efficacy Study of MCLA-145 in Participants With Advanced or Metastatic Malignancies.

  • MCLA-145, een bispecifiek monoclonaal antilichaam, gericht tegen zowel PD-L1 (inhiberend) als CD137 (activerend)